Therapy for isocitrate dehydrogenase 2 (IDH2)R172 -mutant acute myeloid leukaemia.
David C LinchRobert K HillsAlan K BurnettNigel H RussellRosemary E GalePublished in: British journal of haematology (2021)
Although we earlier reported a very poor outcome for younger adult patients with isocitrate dehydrogenase 2 (IDH2)R172 -mutated acute myeloid leukaemia (AML) entered into UK trials compared to IDH2WT and IDH2R140 -mutated patients, this was not corroborated by a study from the German-Austrian AML Study Group. We have therefore investigated a later cohort of IDH2-mutated patients to identify any changes in outcome and whether this could inform the optimal treatment for IDH2R172 AML. We found an improved outcome for IDH2R172 -mutated AML in the later trials and the data suggests that this may be due to the increased use of allogeneic transplantation to consolidate first remission.
Keyphrases
- wild type
- acute myeloid leukemia
- low grade
- end stage renal disease
- ejection fraction
- newly diagnosed
- chronic kidney disease
- bone marrow
- liver failure
- allogeneic hematopoietic stem cell transplantation
- prognostic factors
- dendritic cells
- stem cell transplantation
- intensive care unit
- patient reported outcomes
- acute lymphoblastic leukemia
- mass spectrometry
- respiratory failure
- drug induced
- high grade
- low dose
- big data
- extracorporeal membrane oxygenation
- mechanical ventilation
- ulcerative colitis
- single molecule
- data analysis
- high speed
- cell therapy